Cadence prices underwritten public offering

Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that it has priced an underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $8.00 per share.  The net proceeds from the sale of the shares, after estimated underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $86.2 million.  The offering is expected to close on or about November 16, 2010, subject to customary closing conditions. Cadence has granted the underwriters for the offering an option for a period of 30 days to purchase up to an additional 1,725,000 shares of common stock to cover over-allotments, if any.

Deutsche Bank Securities Inc. is acting as sole book-running manager for the offering.  Leerink Swann LLC is acting as co-lead manager, and JMP Securities, Wedbush PacGrow Life Sciences and Canaccord Genuity Inc. are acting as co-managers for the offering.